Green Thumb Industries (GTBIF) Total Non-Current Liabilities (2019 - 2024)
Green Thumb Industries (GTBIF) posted Total Non-Current Liabilities of $747.9 million for Q4 2024, up 1.05% on a QoQ basis from $740.2 million in Q3 2024, and down 0.75% year-over-year from $753.6 million in Q1 2024.
Green Thumb Industries (GTBIF) Total Non-Current Liabilities (2019 - 2024) Analysis & Trends
Green Thumb Industries' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $747.9 million for Q4 2024.
- Quarterly Total Non-Current Liabilities fell 0.75% year-over-year to $747.9 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $747.9 million (down 0.75% YoY) and the FY2024 annual result came in at $747.9 million, down 0.75% from the prior year.
- Total Non-Current Liabilities was $747.9 million for Q4 2024 at Green Thumb Industries, up from $740.2 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $807.0 million in Q2 2023 and bottomed at $438213.0 in Q2 2021.
- A 5-year average of $342.2 million and a median of $956163.5 in 2020 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities tumbled 32.45% — and 2022, when it surged 169964.33%.
- Green Thumb Industries' Total Non-Current Liabilities stood at $783000.0 in 2020, then slipped by 11.11% to $696000.0 in 2021, then declined by 14.8% to $593000.0 in 2022, then jumped by 126974.37% to $753.6 million in 2023, then slipped by 0.75% to $747.9 million in 2024.
- Business Quant data shows GTBIF's Total Non-Current Liabilities at $747.9 million in Q4 2024, $740.2 million in Q3 2024, and $786.6 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Green Thumb Industries | 1.63 Bn | 1.29 Bn | 143.65 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 747.93 Mn |
| Sep 30, 2024 | 740.15 Mn |
| Jun 30, 2024 | 786.60 Mn |
| Dec 31, 2023 | 753.55 Mn |
| Sep 30, 2023 | 792.31 Mn |
| Jun 30, 2023 | 807.02 Mn |
| Mar 31, 2023 | 780.75 Mn |
| Dec 31, 2022 | 593,000.00 |
| Sep 30, 2022 | 622,000.00 |
| Jun 30, 2022 | 745.24 Mn |
| Mar 31, 2022 | 672,000.00 |
| Dec 31, 2021 | 696,000.00 |
| Jun 30, 2021 | 438,213.00 |
| Mar 31, 2021 | 762,865.00 |
| Dec 31, 2020 | 783,000.00 |
| Sep 30, 2020 | 473,136.00 |
| Jun 30, 2020 | 483,935.00 |
| Mar 31, 2020 | 1.13 Mn |
| Dec 31, 2019 | 137,736.00 |